GLENMARK PHARMACEUTICALS
|
The Current P/E Ratio of GLENMARK PHARMACEUTICALS is 63.73.
| Share Price | ₹2,405.3 | May 19,2026 |
| Market Cap | ₹67,876.2 Cr | |
| Earnings-TTM | ₹1,065.0 Cr | TTM-Consolidated Results |
| Price/Earnings | 63.73x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLENMARK PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹67,876.2 Cr] as on May 19,2026
(/) Earnings [ ₹1,065.0 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 63.73x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay 63.73 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLENMARK PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLENMARK PHARMACEUTICALS
PE Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 22.48x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 13.51x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2023 at 44.14x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does GLENMARK PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 1,065.02 | 63.73 | 67,876.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 41.05 | 451,591.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 74.03 | 183,512.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 66.40 | 150,850.0 |
| CIPLA LTD | 3,869.79 | 29.43 | 113,884.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.87 | 111,339.0 |
| MANKIND PHARMA LTD | 1,796.65 | 57.31 | 102,964.0 |
| LUPIN LTD | 5,355.47 | 19.52 | 104,542.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 20.40 | 102,530.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 24.78 | 87,040.3 |
| LAURUS LABS LTD | 889.85 | 81.60 | 72,610.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLENMARK PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.52x |
| Max industry PE | 81.60x |
| Median industry PE | 41.05x |
| Average industry PE | 45.92x |
You may also like the below Video Courses